(Q38436732)

3 September 2017

The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma (English)

1 reference

3 September 2017

Sorina Granovsky-Grisaru

1

1 reference

3 September 2017

Salah Zaidoun

2

1 reference

3 September 2017

Dan Grisaru

3

1 reference

3 September 2017

Yael Yekel

4

1 reference

3 September 2017

Diana Prus

5

1 reference

3 September 2017

Uziel Beller

6

1 reference

3 September 2017

Rachel Bar-Shavit

7

1 reference

3 September 2017

language of work or name

English

0 references

publication date

27 July 2006

1 reference

3 September 2017

1 reference

3 September 2017

103

1 reference

3 September 2017

3

1 reference

3 September 2017

802-806

1 reference

Thrombin signalling and protease-activated receptors

3 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Protease-activated receptors in hemostasis, thrombosis and vascular biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Protease activated receptors: theme and variations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Human Protease-Activated Receptor 1 Expression in Malignant Epithelia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Thrombin receptor overexpression in malignant and physiological invasion processes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

7 January 2021

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Two pathogenetic types of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Grade of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Current treatment options for endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Bax, Bcl-2, and p53 expression in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Prognostic Significance of E-Cadherin Protein Expression in Pathological Stage I-III Endometrial Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Putting tumours in context

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Epithelial-mesenchymal transition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Hemostatic factors in tumor biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

The cytoplasmic tails of protease-activated receptor-1 and substance P receptor specify sorting to lysosomes versus recycling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.048

10.1016/J.YGYNO.2006.05.048

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference